Anuroop Packaging Q2 Standalone Profit Drops to ₹0.0266 Crore
Key highlights
- Standalone Q2 FY27 revenue from operations fell to ₹0.1452 crore from ₹0.7789 crore in Q2 FY26.
- Standalone Q2 FY27 net profit was ₹0.0266 crore, versus ₹0.0703 crore a year earlier.
- Consolidated Q2 FY27 revenue was ₹1.4416 crore, down from ₹3.0841 crore in Q2 FY26.
- Wada assets with a carrying amount of ₹1.2782 crore were classified as held for sale.
powered by IRIS

Anuroop Packaging Limited reported standalone net profit of ₹0.0266 crore for the quarter ended September 30, 2026, down from ₹0.2041 crore in the preceding quarter and ₹0.0703 crore a year earlier, as standalone revenue from operations fell to ₹0.1452 crore.
Know Anuroop Packaging inside out
Results, valuation, peers and who's buying, in one view.
What did Anuroop Packaging report for Q2 FY27?
Anuroop Packaging reported a sharp decline in standalone revenue and profit for the September 2026 quarter, while its consolidated business remained profitable despite lower revenue. Standalone revenue from operations was ₹0.1452 crore in Q2 FY27, compared with ₹0.5653 crore in Q1 FY27 and ₹0.7789 crore in Q2 FY26.
Standalone net profit after tax stood at ₹0.0266 crore, against ₹0.2041 crore in the immediately preceding quarter and ₹0.0703 crore in the year-earlier quarter. This represents a sequential decline of about 87% in standalone profit and a year-on-year decline of about 62%, based on the reported figures. Total standalone income for the quarter was ₹0.1957 crore.
At the consolidated level, revenue from operations was ₹1.4416 crore, lower than ₹1.9642 crore in Q1 FY27 and ₹3.0841 crore in Q2 FY26. Consolidated net profit after tax was ₹0.3716 crore, compared with ₹0.3641 crore in the previous quarter and ₹0.4213 crore a year earlier.
How were the September quarter results approved?
The Board of Directors approved Anuroop Packaging's unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, at its meeting on November 14, 2026. The results had first been reviewed by the Audit Committee.
The statutory auditors, M/S Sachdev & Co, Chartered Accountants, conducted a limited review of the financial results. A limited review is the standard quarterly review process for listed companies and is narrower in scope than a full annual audit.
The reporting covers both the parent company's standalone operations and the consolidated group. The consolidated figures include subsidiary Yuktarth Advisory Limited, formerly known as Sara Solutions Limited, along with its CMS Pathlabs & Medical Centre division.
How did standalone and consolidated performance compare?
The comparison shows that the consolidated business accounted for substantially more reported revenue and profit than the standalone entity in Q2 FY27. Consolidated revenue of ₹1.4416 crore was nearly ten times the standalone revenue of ₹0.1452 crore for the quarter.
Consolidated revenue declined by about 26.5% from Q1 FY27 and about 53.3% from Q2 FY26. However, consolidated net profit was marginally higher than the preceding quarter by about 2.1%, though it was about 11.8% below the prior-year quarter.
For the six months ended September 30, 2026, standalone net profit after tax was ₹0.2307 crore, compared with ₹0.1405 crore in the corresponding period of the previous year. The half-year result was higher year on year despite the lower profit reported in the September quarter.
Got a follow-up? Ask IRIS
Why has Anuroop Packaging classified Wada assets as held for sale?
Anuroop Packaging classified its Wada land, factory building, plant and machinery, and electrical installation as non-current assets held for sale after shareholders approved the proposed sale. The approval came through a special resolution passed at the Annual General Meeting held on September 24, 2026.
The assets had a carrying amount of ₹1.2782 crore when they were reclassified under Ind AS 105, the accounting standard dealing with non-current assets held for sale and discontinued operations. The company said depreciation on these assets ceased from the date of reclassification.
This classification is important because it separates the identified Wada assets from assets intended for continued use in the ordinary course of operations. The disclosure does not state the transaction value, buyer, completion date, or financial effect of any eventual sale.
What does the result mean for investors and operations?
The quarter highlights a pronounced decline in reported revenue at both standalone and consolidated levels compared with the same period last year. For investors, the difference between standalone and consolidated figures is material because the group results include Yuktarth Advisory and its CMS Pathlabs & Medical Centre division.
Anuroop Packaging reported standalone paid-up equity share capital of ₹11.0530 crore as of September 30, 2026, with other equity of ₹9.4379 crore. These balance-sheet disclosures provide context for the scale of the standalone quarterly revenue and profit numbers.
The Wada asset-sale decision is also relevant to the company's operating structure because it covers land, a factory building, plant and machinery, and electrical installations. The available disclosure confirms the accounting reclassification but does not provide further operational details or a timetable for the asset disposal.
Conclusion
Anuroop Packaging's Q2 FY27 results showed lower standalone revenue and profit, with standalone net profit falling to ₹0.0266 crore. Consolidated revenue also declined from both the preceding quarter and the year-earlier period, although consolidated net profit remained broadly stable sequentially at ₹0.3716 crore.
Investors will watch for updates on the proposed Wada asset sale, including any buyer, sale consideration, and completion timeline. Future quarterly disclosures will also indicate whether revenue trends improve across the standalone business and the consolidated group.


